Condition: Generalized Myasthenia Gravis (gMG) · Sponsor: Miriam Freimer
This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive subcutaneous zilucoplan injections daily for 12 weeks. Participation in the study will last for approximately 18 weeks.
This description comes directly from the study's public registry record.
Julie Agriesti, MACPR, CCRC · 614-293-4098 · Julie.Agriesti@osumc.edu
Always discuss trial participation with your own doctor first.
| The Ohio State University | Columbus, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07215949